42 results match your criteria: "Huntsman Cancer Institute and University of Utah[Affiliation]"
Breast Cancer Res Treat
April 2017
Division of Physical Activity, Prevention and Cancer, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany.
Purpose: Sleep problems frequently affect breast cancer patients during and after treatment and reduce their quality of life. Treatment strategies are mostly unknown. Thus, we assessed within a randomized controlled trial whether a 12-week exercise program starting with the radiotherapy influences sleep trajectories.
View Article and Find Full Text PDFActa Oncol
April 2017
a Division of Physical Activity, Prevention and Cancer , National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg , Germany.
Background: Exercise during and after breast cancer treatment has shown several health benefits. However, little is known about the courses, patterns, and determinants of physical activity of breast cancer patients, and the role of exercise interventions on their physical activity behavior in the long run.
Material And Methods: Self-reported physical activity was assessed in 227 breast cancer survivors before, during, and three, six, and 12 months post-intervention within two randomized resistance exercise trials performed during adjuvant chemo- or radiotherapy, respectively, with similar designs.
Ann Intern Med
September 2016
From Huntsman Cancer Institute and University of Utah Health Sciences, Salt Lake City, Utah.
Oncotarget
October 2016
Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II dose (RP2D), and dose-limiting toxicities (DLTs) of combined mTOR inhibitor sirolimus (1 mg-5 mg PO daily) and HDAC inhibitor vorinostat (100 mg-400 mg PO daily) in patients with advanced cancer. Seventy patients were enrolled and 46 (66%) were evaluable for DLT assessment since they completed cycle 1 without dose modification unless they had DLT.
View Article and Find Full Text PDFNat Commun
March 2016
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA.
Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy with strong heritability. To further understand the genetic susceptibility for CLL and identify common loci associated with risk, we conducted a meta-analysis of four genome-wide association studies (GWAS) composed of 3,100 cases and 7,667 controls with follow-up replication in 1,958 cases and 5,530 controls. Here we report three new loci at 3p24.
View Article and Find Full Text PDFOncoscience
April 2015
Departments of Internal Medicine (Division of Oncology), Huntsman Cancer Institute and University of Utah School of Medicine, Salt Lake City ; Center for Investigational Therapeutics, Huntsman Cancer Institute and University of Utah School of Medicine, Salt Lake City.
Purpose: To identify exceptional responders among patients with advanced pancreatic cancer enrolled in first-in-man (FIM) studies.
Methods: A Scopus search identified 66 FIM studies that enrolled at least one patient with advanced pancreatic cancer between 2002-2012. Descriptive statistics were used to summarize categorical variables.
Cancer Epidemiol Biomarkers Prev
April 2015
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Background: Cigarette smoking (smoking), hormone therapy (MHT), and folate intake (folate) are each thought to influence colorectal cancer risk, but the underlying molecular mechanisms remain incompletely defined. Expression of estrogen receptor β (ESR2) has been associated with colorectal cancer stage and survival.
Methods: In this prospective cohort study, we examined smoking, MHT, and folate-associated colorectal cancer risks by ESR2 protein expression level among participants in the Iowa Women's Health Study (IWHS).
Am J Gastroenterol
September 2014
Division of Gastroenterology, Huntsman Cancer Institute and University of Utah, Salt Lake City, Utah, USA.
Objectives: We performed meta-analysis to estimate pooled prevalence, risk factors, and outcomes of interval colorectal cancers (CRCs).
Methods: Systematic literature search through October 2013, identified population-based studies, reporting prevalence of interval CRCs (CRCs diagnosed within 6-36 months of colonoscopy). We estimated the pooled prevalence, patient, endoscopist, and tumor-related risk factors, as well as outcomes of interval CRCs, as compared with detected CRCs (CRCs diagnosed at or within 6 months of colonoscopy).
Cancer Epidemiol Biomarkers Prev
February 2014
Authors' Affiliations: Departments of Laboratory Medicine and Pathology and Health Sciences Research; Division of Epidemiology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester; Department of Epidemiology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine (Ga
Cigarette smoking (CS), hormone therapy (HT), and folate intake (FI) are each thought to influence colorectal cancer risk, but the underlying molecular mechanisms remain incompletely defined. The TP53 (p53) protein, encoded by the TP53 tumor-suppressor gene that is commonly mutated in colorectal cancer, can be readily assessed to differentiate biologically distinct colorectal cancer subtypes. In this prospective cohort study, we examined CS-, HT-, and FI-associated colorectal cancer risks by TP53 protein expression level among Iowa Women's Health Study (IWHS) participants.
View Article and Find Full Text PDFEndoscopy
June 2014
Department of Gastroenterology, Huntsman Cancer Institute and University of Utah, Salt Lake City, Utah, USA.
Endoscopy
March 2014
Department of Medicine Gastroenterology, Huntsman Cancer Institute and University of Utah, Salt Lake City, Utah 84112, United States of America.
Gastroenterology
August 2013
Department of Medicine, Gastroenterology, Huntsman Cancer Institute and University of Utah, Salt Lake City, Utah, USA.
Background & Aims: Colorectal tumors have a large degree of molecular heterogeneity. Three integrated pathways of carcinogenesis (ie, traditional, alternate, and serrated) have been proposed, based on specific combinations of microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and mutations in BRAF and KRAS. We used resources from the population-based Iowa Women's Health Study (n = 41,836) to associate markers of colorectal tumors, integrated pathways, and clinical and pathology characteristics, including survival times.
View Article and Find Full Text PDFClin Gastroenterol Hepatol
August 2013
Department of Medicine, Gastroenterology, Huntsman Cancer Institute and University of Utah, Salt Lake City, Utah, USA.
Endoscopy
October 2012
Division of Gastroenterology and Hepatology, Huntsman Cancer Institute and University of Utah, Salt Lake City, Utah 84112, USA.
Gastroenterology
May 2012
Huntsman Cancer Institute and University of Utah, Salt Lake City, Utah, USA.
Gastrointest Endosc
December 2012
Huntsman Cancer Institute and University of Utah, Salt Lake City, Utah, USA.
Am J Hematol
February 2005
Department of Radiation Oncology, Huntsman Cancer Institute and University of Utah, Salt Lake City, UT 84132, USA.
Intracranial deposits of extramedullary hematopoiesis are extremely rare, and limited experience with the treatment of these lesions has been reported. Our review of the literature provides further insights regarding the clinical, radiological, and pathological behavior of these lesions and examines the available treatment strategies. Radiation therapy has proven to be an effective modality for treatment of this rare radiosensitive disease.
View Article and Find Full Text PDF